BUSINESSBLOOMBERG
Shionogi-Backed Biotech Apnimed Raises $192 Million in US IPO
Apnimed Inc., a late-stage drug developer focused on sleep apnea, raised $192 million in an upsized US initial public offering, priced at the top of a marketed range. The company is backed by Shionogi.
Related Signal
Adjacent reporting
- Shionogi-Backed Apnimed Seeks to Raise $160 Million in US IPO
- Cancer drug startup Parabilis Medicines is raising a record $670 million in its IPO
- Novo-Backed Drugmaker Avalyn Soars 44% After $300 Million US IPO
- Novo-Backed Drugmaker Avalyn Raises $300 Million in Upsized IPO
- Novo-Backed Biotech Hemab Seeks to Raise $212 Million in US IPO